论文部分内容阅读
目的:探讨吡格列酮对2型糖尿病肾病患者基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)水平的影响。方法:选择早期2型糖尿病肾病患者40例,随机分为治疗组和对照组,治疗组在对照组常规降糖降压的基础上,加用吡格列酮30mg,po,qd,疗程12周采用酶联免疫吸附法(ELISA)测定两组患者治疗前后MMP-2水平,并测定尿白蛋白/肌酐(ACR)。结果:治疗组治疗后MMP-2水平、ACR与治疗前比较,差异具统计学意义(P<0.01),而对照组无明显差异(P>0.01)。治疗组治疗后MMP-2水平、ACR与对照组比较,差异也具统计学意义(P<0.01)结论:吡格列酮可能通过升高MMP-2水平延缓糖尿病进展。
Objective: To investigate the effect of pioglitazone on the level of matrix metalloproteinase-2 (MMP-2) in patients with type 2 diabetic nephropathy. Methods: Forty patients with early stage type 2 diabetic nephropathy were randomly divided into treatment group and control group. The treatment group was given pioglitazone 30 mg, po, qd on the basis of conventional blood glucose lowering and blood pressure control. The level of MMP-2 in the two groups before and after treatment was measured by ELISA, and the urinary albumin / creatinine (ACR) was measured. Results: After treatment, the levels of MMP-2 and ACR in the treatment group were significantly different from those before treatment (P <0.01), while there was no significant difference in the control group (P> 0.01). The level of MMP-2 and ACR in the treatment group were also significantly different from those in the control group (P <0.01). Conclusion: Pioglitazone can delay the progression of diabetes by increasing the level of MMP-2.